Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: A randomized controlled trial

Pharmacogenomics

Volumn 14, Issue 13, 2013, Pages 1593-1603

  Jonas, Daniel E ^a,b,c   Evans, James P ^a   McLeod, Howard L ^b   Brode, Shannon ^c,d   Lange, Leslie A ^a   Young, Mary L ^a   Shilliday, Betsy Bryant ^a,b   Bardsley, Michelle Martensen ^b   Swinton Jenkins, Nia J ^b,e   Weck, Karen E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d HAYES Plus Inc   (United States)

^e PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

anticoagulation; clinical trial; genetics; pharmacogenetics; pharmacogenomics; warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYP2C9 GENE; DRUG EFFECT; DRUG EFFICACY; EMERGENCY HEALTH SERVICE; FEMALE; GENE; GENETIC ALGORITHM; GENOTYPE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; VKORC1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAMIN K EPOXIDE REDUCTASES; WARFARIN; YOUNG ADULT;

EID: 84885399547     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.145     Document Type: Article

References (25)

1. Hafner JW, Belknap SM, Squillante MD, Bucheit KA. Adverse drug events in emergency department patients. Ann. Emerg. Med. 39(3), 258-267 (2002).
2. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 119(Suppl. 1), S108-S121 (2001).
3. Fihn SD, McDonell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann. Intern. Med. 118(7), 511-520 (1993).
4. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am. J. Med. 95(3), 315-328 (1993).
5. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91(1), 87-94 (2004).
6. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci. 30(7), 375-386 (2009). Describes the genetic and clinical factors associated with warfarin dosing, including recent developments. The review concluded that whether genotype-guided dosing is clinically beneficial remains unclear, but studies are currently underway that will help to determine this.
7. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009). CYP2C9 and VKORC1 significantly influenced warfarin dose and predicted individuals who were predisposed to unstable anticoagulation. The results suggest that initiation of warfarin guided by pharmacogenetics could improve clinical outcome.
8. Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009). The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach.
9. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005).
10. Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
11. Tham LS, Goh BC, Nafziger A et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80(4), 346-355 (2006).
12. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, g-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95(5), 782-787 (2006).
13. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: Proposal for a new dosing regimen in Chinese patients. Eur. J. Clin. Pharmacol. 63(12), 1135-1141 (2007).
14. Wu AH, Wang P, Smith A et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: Comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008).
15. Burmester JK, Berg RL, Yale SH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6), 509-518 (2011). Genotype-informed dosing improved the prediction of therapeutic dose beyond that available with clinical parameters. Genetic information did not affect time in therapeutic target range during the first 14 days of therapy.
16. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007). An algorithm guided by pharmacogenetic and clinical factors improved the accuracy of warfarin dose initiation, but this study found no statistically significant differences between groups for their primary clinical end points.
17. Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16), 1997-2005 (2012).
18. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2008). CYP2C9 genotype-guided warfarin therapy was found to be more efficient and safer than the ?average-dose? protocol.
19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), S160-S198 (2008).
20. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
21. Rosendaal FR, Cannegieter SC, Van Der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69(3), 236-239 (1993).
22. Jonas DE, Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements for anticoagulation therapy with warfarin. Med. Decis. Making 30(2), 206-216 (2010).
23. Borgiani P, Ciccacci C, Forte V et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2), 261-266 (2009).
24. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
25. Ferder NS, Eby CS, Deych E et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 8(1), 95-100 (2010).